Health officials have given a life-extending drug the green light for widespread NHS, giving hope to thousands of men facing a "death sentence" from prostate cancer.
The National Institute for Health and Care Excellence (Nice) said the drug enzalutamide, also known as xtandi, should be considered for use in the treatment of men with hormone relapsed prostate cancer that has spread to other parts of the body.
Nice said in its draft guidance that it was pleased to recommend the drug, which is manufactured by Astellas Pharma, for patients who have few other treatment options left.
More top news
At least one person has died in the crash after the plane came down in the city of Riverside shortly after take off.
The animal is believed to have been attacked with metal bars, knives and rocks and later died of his injuries.
More than 20,000 allegations of abuse by care home workers have been made in the last three years, figures show.